Reasons to Invest

The table below summarises how our key strategic areas are linked to our risks and key performance indicators and highlights what our mid-term priorities are. This provides an user friendly guide on how to access further information in this report.

Read more
Our Strategy
  • Deliver the pipeline
  • Focus on specialist therapeutic areas
  • In-license opportunities
  • Innovative management team
  • Efficient effective operations
  • Wide range of scale and dosage forms
  • Profitable third party contracts
  • End-to-end service
  • Experienced sales and marketing teams focused on clearly defined therapeutic areas
  • Expand into additional territories
  • Leaders in continuous education programmes for veterinarians
  • Continue to grow sales and profit
  • Generate value by investing in the pipeline, maximising existing portfolio and expanding geographically
Risks
  • Failure of clinical trials
  • Failure to meet regulatory requirements under which we operate
  • Loss of key personnel
  • Failure of a major supplier
  • Failure to meet regulatory requirements under which we operate
  • Loss of key personnel
  • Competitor products launched against one of our leading brands
  • Revenue from recently launched new products failing to meet expectations
  • Prescribing pressure on veterinarians to reduce antibiotic use
  • Loss of key personnel
  • Mitigation plans are in place to reduce the potential impact of the identified risks on Shareholder value
Mid-term Priorities
  • Manage four products in clinical phase
  • Complete filing on two major products
  • Evaluate new opportunities
  • Drive ongoing efficiency improvements
  • Extend FDA approval into new dosage forms for the Skipton site
  • Implement Oracle IT system at the Bladel Site
  • Establish Dechra subsidiaries in new territories
  • Further investment in US sales and marketing team as the pipeline delivers
  • Maintain organic growth of key products
  • Maximise the return on new product launches
  • Sustain growth
  • Leverage strong balance sheet
  • Generate strong cash conversion
KPIs (pre-divestment of Services)
  • Pharmaceutical product development pipeline
  • Employees
  • Health and safety performance
  • Employees
  • Revenue from key pharmaceutical products
  • Revenue from specialist pet diets
  • Employees
  • Underlying operating profit margin
  • Cash conversion rate
  • Return on capital employed